Literature DB >> 24241966

Impact of thoracic recurrent laryngeal node dissection: 508 patients with tri-incisional esophagectomy.

Zihui Tan1, Guowei Ma, Jinming Zhao, Amos Ela Bella, Tiehua Rong, Jianhua Fu, Yuqi Meng, Kongjia Luo, Dongrong Situ, Peng Lin.   

Abstract

BACKGROUND: To evaluate the feasibility and safety of recurrent laryngeal nerve (RLN) lymph node (LN) dissection, this study compared the postoperative complications and survival between modern two-field lymphadenectomy (MTL) and modified standard two-field lymphadenectomy (MSTL) by using the propensity score matching method.
METHODS: After generating propensity scores given the covariates of age, sex, tumor length, tumor location, tumor grade, and clinical stage, 254 patients with MTL were matched to 254 MSTL patients using the nearest available score matching. The LNs resected during MSTL were paraesophageal and preparatracheal LNs in the upper mediastinum, in addition to those resected during standard two-field lymphadenectomy.
RESULTS: RLN LNs were those most commonly affected by nodal metastasis in our series (26 %). Metastasis in RLN LNs was found in around 35, 25, and 20 % of patients with cancer in the upper, middle, and lower thoracic esophagus, respectively. LN metastasis was confined to the RLN region in 49 patients. Even 35 % of patients with pT1 tumors had positive RLN LNs. MTL increased the mean number of resected LNs when compared to MSTL (29 vs.15; p < 0.001). Recurrence was more frequent in those assigned MSTL than those assigned MTL (p < 0.001). The 5-year overall survival (OS) and disease-free survival (DFS) rate for MTL were 50.7 and 42 % compared to 35.3 and 28.2 % for MSTL (both p < 0.001), respectively. Postoperative complications were more frequent following MTL when compared to the MSTL. However, no statistically significant difference in postoperative complications was observed between the two groups.
CONCLUSIONS: Adding the removal of RLN LNs might improve OS and DFS with acceptable morbidity for patients with ESCC.

Entities:  

Mesh:

Year:  2013        PMID: 24241966     DOI: 10.1007/s11605-013-2411-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  17 in total

1.  Three-field dissection for squamous cell carcinoma in the thoracic esophagus.

Authors:  Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Kazuo Shirouzu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 1.520

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  Prognostic value of thoracic recurrent nerve nodal involvement in esophageal squamous cell carcinoma.

Authors:  B Malassagne; E Tiret; D Duprez; J Coste; J P de Sigalony; R Parc
Journal:  J Am Coll Surg       Date:  1997-09       Impact factor: 6.113

4.  Experimental studies on the lymphatics of the esophagus from the surgical point of view.

Authors:  S Shiraha
Journal:  Nihon Geka Hokan       Date:  1969-07-01

5.  Lymph node metastasis along the recurrent nerve chain is an indication for cervical lymph node dissection in thoracic esophageal cancer.

Authors:  H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

6.  Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy.

Authors:  Brendon M Stiles; Abu Nasar; Farooq A Mirza; Paul C Lee; Subroto Paul; Jeffrey L Port; Nasser K Altorki
Journal:  Eur J Cardiothorac Surg       Date:  2012-04-04       Impact factor: 4.191

7.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

8.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Recurrence of intrathoracic esophageal cancer.

Authors:  K Isono; S Onoda; K Okuyama; H Sato
Journal:  Jpn J Clin Oncol       Date:  1985-03       Impact factor: 3.019

10.  Total number of resected lymph nodes predicts survival in esophageal cancer.

Authors:  Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

View more
  13 in total

1.  Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma.

Authors:  Samina Park; Yoohwa Hwang; Hyun Joo Lee; In Kyu Park; Young Tae Kim; Chang Hyun Kang
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models.

Authors:  Chenyi Xie; Yihuai Hu; Varut Vardhanabhuti; Hong Yang; Lujun Han; Jianhua Fu
Journal:  Ann Surg Oncol       Date:  2022-08-26       Impact factor: 4.339

3.  Is Prophylactic Cervical Drainage Effective in Patients Undergoing McKeown Esophagectomy Reconstructed Through the Retrosternal Route with Two-Field Lymphadenectomy?

Authors:  Daisuke Fujiwara; Masayuki Watanabe; Yasukazu Kanie; Suguru Maruyama; Kei Sakamoto; Akihiko Okamura; Jun Kanamori; Yu Imamura; Shinji Mine
Journal:  World J Surg       Date:  2022-04-20       Impact factor: 3.282

4.  Incidence and Predictors of Unsuspected Recurrent Laryngeal Nerve Lymph Node Metastases After Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma.

Authors:  Zhi-Gang Li; Xiao-Bin Zhang; Yu-Wen Wen; Yun-Hen Liu; Yin-Kai Chao
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

5.  Application of Endobronchial Ultrasonography for the Preoperative Detecting Recurrent Laryngeal Nerve Lymph Node Metastasis of Esophageal Cancer.

Authors:  Hong-Bo Shan; Rong Zhang; Yin Li; Xiao-Yan Gao; Shi-Yong Lin; Guang-Yu Luo; Jian-Jun Li; Guo-Liang Xu
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

6.  Efficacy comparison of transcervical video-assisted mediastinoscopic lymphadenectomy combined with left transthoracic esophagectomy versus right transthoracic esophagectomy for esophageal cancer treatment.

Authors:  Xu Li; Wenxiang Wang; Yong Zhou; Desong Yang; Jie Wu; Baihua Zhang; Zhining Wu; Jinming Tang
Journal:  World J Surg Oncol       Date:  2018-02-09       Impact factor: 2.754

7.  Comparison of minimally invasive Ivor Lewis esophagectomy and left transthoracic esophagectomy in esophageal squamous cell carcinoma patients: a propensity score-matched analysis.

Authors:  Qi Wang; Zixiang Wu; Tianwei Zhan; Shuai Fang; Sai Zhang; Gang Shen; Ming Wu
Journal:  BMC Cancer       Date:  2019-05-27       Impact factor: 4.638

8.  Safety and oncological efficacy of bilateral recurrent laryngeal nerve lymph-node dissection after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: a propensity-matched analysis.

Authors:  Yin-Kai Chao; Chien-Hung Chiu; Yun-Hen Liu
Journal:  Esophagus       Date:  2019-08-19       Impact factor: 4.230

9.  Diagnostic value of intraoperative ultrasonography in assessing thoracic recurrent laryngeal nerve lymph nodes in patients with esophageal cancer.

Authors:  Jianwei Wang; Min Liu; Jingxian Shen; Haichao Ouyang; Xiuying Xie; Ting Lin; Anhua Li; Hong Yang
Journal:  BMC Cancer       Date:  2018-07-13       Impact factor: 4.430

10.  Comparative study of three types of lymphadenectomy along the left recurrent laryngeal nerve by minimally invasive esophagectomy.

Authors:  Shuangping Zhang; Peng Zhang; Shiping Guo; Jianhong Lian; Yun Chen; Ailan Chen; Yong Ma; Feng Li
Journal:  Thorac Cancer       Date:  2019-12-20       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.